Tech mega-operation: Nvidia 33 million buy SoftBank ARM chip maker - Technological operation in sight.
The US-based multinational Nvidia is close to sealing an agreement to acquire the British microprocessor manufacturer ARM Holdings, in the hands of SoftBank, for more than 40,000 million dollars (about 33,760 million euros at current exchange rate), according to Reuters.
The sale, which should be approved by regulatory authorities, could be a historic milestone in the semiconductor sector. A few months ago, Maxim Integrated Product acquired Analog Devices for $ 22 billion.
SoftBank, arm's current owner, had been searching for a buyer for some time and seems to have found it.
And it is that, for weeks, it was already rumored that the negotiations between the American giant and the Japanese company could be forging.
In this regard, the agreement could be announced next week, which would mean for Nvidia to take over the company that is behind the microprocessors of many of the smartphones that exist on the market.
The company, for now controlled by SoftBank, is not well known to the end consumer. However, its function is key in the smartphone business, as it provides the basic architecture that is then licensed and used by most manufacturers of mobile processors, from Qualcomm (Snapdragon) to Samsung (Exynos), Apple or Huawei.
Nvidia 33 million buy SoftBank ARM chip maker
Currently, Arm is expanding to automotive processors, data center services and other devices.
For its part, Nvidia is known for its graphics chips that boost video games - whose demand has skyrocketed by the coronavirus— but also has a presence in other segments, including artificial intelligence, autonomous cars and data centers.
Arm and Nvidia have collaborated before.
In fact, last year Nvidia claimed it would run its chips with ARM processors with the aim of building supercomputers - which are computing devices with computing capabilities superior to ordinary and desktop computers and which are used for specific purposes.
This would deepen their push into systems that are used to model both climate change predictions and nuclear weapons, according to Reuters.
SoftBank acquired Arm for $ 32 billion ($27 billion at current exchange rate) in 2016. It was the biggest purchase in its history. The Japanese company sought to expand to the technology of the Internet of things, which consists of a digital interconnection of everyday objects.
In this sense, an agreement would allow it to make a return on that huge investment, which it has been unable to grow, at a time when the UK-based company is more influential than ever.
For its part, Nvidia, which is already one of the most important semiconductor manufacturers in the world, would acquire a company that would boost its relevance in the technological market.
End of Nvidia 33 million buy SoftBank ARM chip maker
There will not be enough vaccines for everyone until 2024, according to one of the world's largest producers
One of the world's largest vaccine producers has warned that there will not be enough doses against coronavirus for everyone until at least 2024.
"It will be 4 or 5 years before everyone gets their vaccine," Adar Poonawalla, CEO of the Serum Institute of India, tells The Financial Times.
Poonawalla's time frame is similar to that of the scientific director of the World Health Organization (who), Soumya Swaminathan, who believes that, at the moment, a vaccine seems the best way out of this but there are still many 'buts' about its effectiveness and safety.
This institute has already partnered with pharmaceutical companies such as AstraZeneca and Novavax to develop the vaccine and produce 1 billion doses, half of which are for India, and is in negotiations with Russia's Gamaleya Institute to develop Sputnik, according to the Financial Times.
The Poonawalla statements contradict the promises of several world leaders who have promised them by the end of this year. Some experts already warn that the urgency of the vaccine could put the population at risk and worsen the pandemic situation.
"There is a danger that political and economic pressures for rapid procurement of a COVID-19 vaccine may lead to widespread deployment of a weakly effective vaccine, due to a deceptively promising outcome of a low-potency trial," notes a group of who solidarity vaccine trials experts in a joint article in The Lancet.
With the wealthiest countries making large reserves and purchases without a guarantee that the trials will be authorized, the manager does not forget the developing countries, at the end of the queue to get doses. Part of its agreement with AstraZeneca provides for the production of vaccines at a cost of around EUR 2.5 per dose for 68 countries and, with Novavax, for 92.
The WHO warned in August against the dangers of "vaccine nationalism" and urged wealthier countries not to keep COVID-19 treatments to themselves.
"For the world to recover faster, it has to recover together because it is a globalized world: economies are intertwined. One part of the world or a few countries cannot be a safe haven, " said WHO Director general Tedros Adhanom Ghebreyesus at the Aspen Security Forum.